The AstraZeneca CCP virus vaccine has been found to be mostly effective against the United Kingdom variant, according to preliminary data published on Feb. 4. The B.1.1.7 variant has been responsible for most CCP virus cases in the United Kingdom after it first emerged in the country last November. The variant has also been detected in the United States. “Data from our trials of the ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus but also protects against the novel variant, B.1.1.7, which caused the surge in disease from the end of 2020 across the UK,” Andrew Pollard, professor of pediatric infection and immunity and chief investigator of the Oxford vaccine trial, said in a statement. Oxford University is a co-developer of the AstraZeneca vaccine, which uses a modified chimpanzee common cold virus (adenovirus) to instruct the cells inside the body to …